Sign in
CompletedPhase 4

An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

Key facts

Who runs it
CSL Behring
Where
Baltimore, Centennial, Litchfield Park, Oklahoma City, Pittsburgh, Plymouth, Scottsdale, and St Louis, United StatesSee the 8 sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
8 people enrolled
Started
15 Jul 2025
Ended
30 Jun 2026
Type of study
Interventional
Treatments tested
  • IgPro
Record updated
16 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Participants must be aged >=18 years
  • Participants must have a confirmed and documented diagnosis of PID, must be IG treatment-naïve and have an IgG level less than or equal to (<=) 400 milligrams per deciliter(mg/dL) at Screening

Who cannot take part

  • Participants who are receiving the following medications:
  • Systemic corticosteroids (prednisone or equivalent; average daily dose of greater than [>] 15 mg) from 4 weeks before Screening
  • Any dose of systemic immunosuppressants within 9 months or 5 times the half-life (t½) plus 6 months before Screening, whichever is longer
  • Any dose of biologic therapies with influence on the immune system (eg, tumor necrosis factor inhibitors, interleukin inhibitors, B-cell inhibitors), including investigational agents, within 12 months or 5 times the t½ plus 6 months before Screening, whichever is longer
  • Participants who are currently receiving anti-coagulation therapy
  • Participants with a documented history or a current diagnosis of a thromboembolic event(s) (eg, deep vein thrombosis, pulmonary embolism, myocardial infarction, cerebrovascular accident, transient ischemic attack) or coagulopathy within 12 months before Screening
  • Participants with hypoalbuminemia, protein-losing enteropathies, and kidney diseases with proteinuria
  • Participants with severe dehydration and known blood disorders affecting viscosity
  • Participants with new onset or worsening or severe cardiac, pulmonary, kidney disease, and liver disease
  • Participants with malignancies of lymphoid cells such as chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and immunodeficiency with thymoma
  • Participants with aspartate aminotransferase and alanine aminotransferase concentration > 3 times the upper limit of normal (ULN; central laboratory) at Screening
  • Participants with creatinine concentration > 1.5 times the ULN (central laboratory) at Screening
  • Participants with hyperprolinemia

Where in United States

  • Johns Hopkins Bayview Medical CenterBaltimore, United States
  • Immunoe Health CentersCentennial, United States
  • Research Solutions of AZLitchfield Park, United States
  • Allergy Asthma and Clinical Research CenterOklahoma City, United States
  • Allergy & Clinical ImmunologyPittsburgh, United States
  • Midwest ImmunologyPlymouth, United States
  • Medical Research of ArizonaScottsdale, United States
  • Washington UniversitySt Louis, United States

About the trial

What the trial wants to find out

This is an open-label, multicenter, phase 4 study in IG treatment-naïve participants with PID, conducted in the United States (US), to assess the PK, safety, and tolerability of IgPro20. The primary objective of this study is to characterize the PK of IgPro20 and to assess the safety and tolerability of IgPro20 in IG treatment-naïve participants with PID who are aged greater than or equal to (>=) 18 years.

The group in the trial

  • IgPro20Treatment being tested

    All participants will receive a loading dose of IgPro20 daily from Day 1 to 5 in Week 1, followed by weekly administration of the maintenance dose of IgPro20 from Day 8 (Week 2) to Day 78 (Week 12).

    Treatment: IgPro

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-naïve Subjects With Primary Immunodeficiency
Record updated
16 July 2026